Travere Therapeutics Inc (NASDAQ:TVTX) price on Thursday, April 10, fall -5.99% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $13.49.
A look at the stock’s price movement, the close in the last trading session was $14.35, moving within a range at $13.175 and $14.555. The beta value (5-Year monthly) was 0.842. Turning to its 52-week performance, $25.29 and $5.12 were the 52-week high and 52-week low respectively. Overall, TVTX moved -29.99% over the past month.
Travere Therapeutics Inc’s market cap currently stands at around $1.20 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-19.
Analysts have a consensus estimate of 76.86M for the company’s revenue for the quarter, with a low and high estimate of 72.1M and 94.5M respectively. The average forecast suggests up to a 85.76% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 387.54M, representing a 66.20% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that TVTX is a 50% Sell. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 8 recommend TVTX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
TVTX’s current price about -26.61% and -32.33% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 25.54, while 7-day volatility ratio is 12.78% and 7.20% in the 30-day chart. Further, Travere Therapeutics Inc (TVTX) has a beta value of 0.96, and an average true range (ATR) of 1.40. Analysts have given the company’s stock an average 52-week price target of $30, forecast between a low of $27 and high of $33. Looking at the price targets, the low is -100.15% off current price level while to achieve the yearly target high, price needs to move -144.63%. Nonetheless, investors will most likely welcome a -122.39% jump to $30 which is the analysts’ median price.
If we refocus on Travere Therapeutics Inc (NASDAQ:TVTX), historical trading data shows that trading volumes averaged 2.33 over the past 10 days and 1.78 million over the past 3 months. The company’s latest data on shares outstanding shows there are 87.45 million shares.
The 1.50% of Travere Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 109.18% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 11.19 million on 2025-03-14, giving us a short ratio of 6.65. The data shows that as of 2025-03-14 short interest in Travere Therapeutics Inc (TVTX) stood at 1270.0 of shares outstanding, with shares short falling to 11.3 million registered in 2025-02-14. Current price change has pushed the stock -22.56% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the TVTX stock continues to rise going into the next quarter.
